Maze Therapeutics (MAZE) Operating Income (2024 - 2026)
Maze Therapeutics (MAZE) posted Operating Income of -$26.6 million for Q1 2026, up 30.23% sequentially from -$38.1 million in Q4 2025, and up 24.99% YoY from -$21.2 million in Q1 2025.
Maze Therapeutics (MAZE) Operating Income (2024 - 2026) Analysis & Trends
Maze Therapeutics has reported Operating Income for 3 years, with the latest figure at -$26.6 million in Q1 2026.
- Quarterly Operating Income rose 24.99% year-over-year to -$26.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$134.1 million (down 367.04% YoY) and the FY2025 annual result came in at -$142.9 million, down 348.15% from the prior year.
- Operating Income rose to -$26.6 million in Q1 2026 per MAZE's latest filing, from -$38.1 million in the prior quarter.
- Over five years, Operating Income peaked at $139.6 million in Q2 2024 and troughed at -$38.1 million in Q4 2025.
- A 3-year average of -$12.4 million and a median of -$29.7 million in 2024 frame the typical range for Operating Income.
- The sharpest annual moves came in 2025 and 2026: Operating Income sank 126.14% in 2025, then rose 24.99% in 2026.
- Over 3 years, Operating Income stood at -$29.7 million in 2024, then retreated by 28.03% to -$38.1 million in 2025, then soared by 30.23% to -$26.6 million in 2026.
- According to Business Quant data, Operating Income over the past three periods registered -$26.6 million, -$38.1 million, and -$33.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,158.03 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Maze Therapeutics | 1.51 Bn | 1.51 Bn | - | -48.04 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -48.04 Mn |
| Mar 31, 2026 | -26.55 Mn |
| Dec 31, 2025 | -38.06 Mn |
| Sep 30, 2025 | -32.97 Mn |
| Jun 30, 2025 | -36.47 Mn |
| Mar 31, 2025 | -35.40 Mn |
| Dec 31, 2024 | -29.73 Mn |
| Sep 30, 2024 | -24.23 Mn |
| Jun 30, 2024 | 139.56 Mn |
| Mar 31, 2024 | -28.01 Mn |